Vagus Nerve Stimulation Training Programme for Healthcare Practitioners Launched

Parasym launches a CPD-accredited AVNT™ training programme for healthcare practitioners - covering vagus nerve stimulation science, clinical evidence, and protocols for clinics integrating the wearable Nurosym device.

London, United Kingdom, October 12, 2026 /PressCable/ -- New opportunities to become a certified AVNT™ practitioner are now available as Parasym announces a CPD-accredited training programme for Nurosym - its CE-marked neuromodulation wearable. The programme covers the science behind the company’s vagus nerve stimulation technology, the clinical studies that support it, and the protocols recommended for usage in practice.

For more information, visit: https://nurosym.com/pages/for-professional

Nurosym is a CE-marked Class IIa medical device consisting of a small earpiece that clips onto the tragus - the point where the vagus nerve reaches the surface of the ear. The device is designed to deliver gentle electrical pulses through this point using Parasym's proprietary AVNT™ waveform - targeting a nerve that plays a crucial role in how the body manages stress, rest and recovery.

The company reports more than 60 completed clinical studies, over 100 ongoing studies, and north of 150 research partners accumulated over the course of Nurosym’s development. Moreover, the device is referred to as the most studied wearable vagus nerve stimulation device available - giving practitioners a substantial body of research to draw upon when considering this technology for their own patients.

And the training programme extends beyond theory, with Parasym revealing that enrolled healthcare professionals are able to trial Nurosym directly with users. Meanwhile, access to the company's scientific research team and dedicated professional pricing is available for clinics and medical spas looking to integrate the device into patient care.

The programme builds on an existing base of professional engagement: Nurosym is already recommended by more than 1,000 healthcare professionals worldwide, and the company describes the new offering as a structured way to deepen practitioners' understanding of this fast-emerging technology.

More patients stand to benefit as a result, says the Parasym team. Clinical studies with prominent institutions have shown measurable change in vagus nerve activity, heart rate variability, fatigue, anxiety and depressive states following the device’s implementation. As such, the training programme is designed to help practitioners understand this evidence and apply it as a non-drug approach to nervous system support within their own practice - with Parasym encouraging interested parties to review the clinical evidence and training structure in full before applying.

For more information about Nurosym and its neuromodulation capabilities, visit: https://nurosym.com/

Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as medical claims or guaranteed individual outcomes. Nurosym is a CE-marked medical device in Europe.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nurosym by Parasym
Address: 18 Saint Cross Street 4th Floor, London, England EC1N 8UN, United Kingdom
Website: https://nurosym.com/

Source: PressCable

Release ID: 89205837

In case of identifying any errors, concerns, or inconsistencies within the content shared in this press release that necessitate action or if you require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team is committed to addressing your concerns within 8 hours by taking necessary actions diligently to rectify any identified issues or supporting you with the removal process. Delivering accurate and reliable information remains our top priority.